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ABSTRACT
Background and Objectives: Despite the favorable efficacy of new antiplatelet agents 
demonstrated in randomized controlled trials, their clinical implications in Korea are 
unclear. The purpose of this study was to investigate trends in antiplatelet agent use for acute 
myocardial infarction (AMI) and their impact on 30-day clinical outcomes.
Methods: AMI patients undergoing percutaneous coronary intervention between 2010 and 
2015 were assessed using claim data from the Health Insurance Review and Assessment 
Service.
Results: The use of new antiplatelet agents has rapidly increased since 2013 and has been 
preferred over clopidogrel (Plavix; Bristol-Myers Squibb/Sanofi Pharmaceuticals) since 2015. 
Both prasugrel (Effient; Eli Lilly and Company) (odds ratio [OR], 0.45; 95% confidence 
interval [CI], 0.31–0.67; p<0.001) and ticagrelor (Brilinta; AstraZeneca Pharmaceuticals 
LP) (OR, 0.84; 95% CI, 0.71–0.98; p=0.032) had an independent effect on lowering 30-day 
mortality in a weighted multivariable logistic regression model. However, new antiplatelet 
agents had no significant effect on other clinical outcomes including myocardial infarction, 
stroke, bleeding, and readmission within 30 days.
Conclusion: The use of new antiplatelet agents is rapidly increasing, and they have been used 
more commonly than clopidogrel since 2015. We demonstrated that new antiplatelet agents 
have a favorable effect on reducing 30-day mortality in AMI patients in Korea.
Keywords: Myocardial infarction; Prasugrel; Ticagrelor; Clopidogrel; Percutaneous coronary 
intervention
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INTRODUCTION
Obtaining sufficient platelet inhibition using aspirin and P2Y12 receptor antagonist has been 
a mainstay of treatment for acute myocardial infarction (AMI). Clopidogrel, an irreversible 
P2Y12 inhibitor (Plavix; Bristol-Myers Squibb/Sanofi Pharmaceuticals, Bridgewater, NJ, USA), 
has been widely used for coronary artery disease including AMI. However, there have been 
concerns about its genetic susceptibility and delayed-onset antiplatelet effect.
New P2Y12 receptor antagonists including prasugrel (Effient; Eli Lilly and Company, 
Indianapolis, IN, USA) and ticagrelor (Brilinta; AstraZeneca Pharmaceuticals LP, 
Wilmington, DE, USA) have demonstrated better clinical efficacy as well as more potent 
platelet inhibition compared to clopidogrel in AMI.1)2) Contemporary clinical practice 
guidelines now preferentially recommend new antiplatelet agents over clopidogrel for 
patients with AMI.3-5) These drugs became available in January 2011 and have been covered by 
national health insurance since July 2012 in Korea.
However, there is not sufficient data available regarding the changes in and current status 
of new antiplatelet drug use and the clinical implications. We sought to investigate trends 
in antiplatelet agent use and their impact on clinical outcomes in AMI patients using the 
national health insurance database in Korea.
METHODS
Study population
Korea has a universal national health insurance system that covers approximately 98% of the 
Korean population.6) We used claim data from the Health Insurance Review and Assessment 
Service (HIRA) including age, sex, diagnosis, procedure, surgery, and prescribed medications 
for analyses in this study. HIRA independently conducted the identification and sampling 
of information from the database. All processed data was provided after blinding personally 
identifiable information.
We extracted all patients who were admitted to healthcare service providers for AMI 
and underwent percutaneous coronary intervention (PCI) between 2010 and 2015. The 
International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) 
diagnostic codes I21, I22, and I23 defined patients with AMI. Subcategorical codes including 
I21.0, I21.1, I21.2, I21.3 indicated ST-segment elevation myocardial infarction (STEMI), and 
I21.4 represented non-ST-segment elevation myocardial infarction (NSTEMI). The rest of the 
codes represented an unspecified myocardial infarction (MI). The patients were categorized 
into 3 groups for clopidogrel, prasugrel, and ticagrelor according to the most prescribed P2Y12 
inhibitor during admission. Because few AMI patients were treated with new antiplatelet agents 
until 2012 (Figure 1A and 1B), we used patients between 2013 and 2015 for comparative analyses 
of the 3 different antiplatelet agents. A total of 53,221 AMI patients were identified during this 
period (Figure 1C). As prasugrel was not recommended and was rarely prescribed for patients 
≥75 years old, we included 40,706 patients after exclusion of elderly patients (Figure 1C and 1D).
Hospitals were categorized by the mean number of PCI cases per year for AMI as <50 cases, 
50–150 cases, and >150 cases. Clinical outcomes of all-cause death, recurrent MI, stroke, 
bleeding, and readmission within 30 days after PCI were evaluated. All death and readmission 
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events were identifiable from the database. Other clinical events were determined by further 
admission with a new corresponding diagnostic code after discharge. Stroke, including 
both hemorrhagic and ischemic stroke, was determined by diagnostic codes I60 to I63. We 
obtained intracranial, gastrointestinal, and other bleeding events using the following codes: 
D62, D68.3, D69, I60.x, I61.x, I62.x, I85.01, I85.11, K25.0, K25.2, K25.4, K25.6, K26.0, 
K26.2, K26.4, K26.6, K27.0, K27.2, K27.4, K27.6, K28.0, K28.2, K28.4, K28.6, K29.01, 
K29.21, K29.31, K29.41, K29.51, K29.61, K29.71, K29.81, K29.91, and R58 (Supplementary 
Table 1 in the online-only).
Because the personally identifiable information of each individual was encrypted before 
patient-level analysis to protect privacy, the study was exempted from full review by the 
Institutional Review Board of Severance Hospital, Yonsei University College of Medicine, and 
the requirement for obtaining informed consent was waived. The Institutional Review Board 
of Severance Hospital, Yonsei University College of Medicine approved this study.
Statistical analyses
Categorical data are expressed as number (%) and were analyzed with the χ2 test. Age is 
expressed as median (interquartile range [IQR]) and was compared using the Mann-Whitney 
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Drug Clopidogrel Prasugrel Ticagrelor
Total 53,221 AMI patients Total 40,706 AMI patients
Figure 1. The use of P2Y12 antagonists in patients with AMI. Trends over time of P2Y12 antagonist use (A) and proportion of these prescriptions during 2010–2012 
and 2013–2015 (B). Density plot indicates the age distribution of the 3 antiplatelet agents clopidogrel, prasugrel, and ticagrelor before (C) and after (D) 75 years 
of age. Orange indicates clopidogrel, green indicates prasugrel, and red indicates ticagrelor. 
AMI = acute myocardial infarction.
test because of the skewed distribution after truncation. Absolute standardized mean 
differences were calculated as the difference in mean rates of each variable between the 
treatment group and the total population divided by the standard deviation of the difference. 
The inverse probability of treatment-weighted estimation was applied to minimize 
imbalances of observed covariates.
We utilized generalized boosted models to estimate the propensity score weight of each 
treatment using methods developed for comparison of multiple treatments. The average 
treatment effect on the population weights was estimated using the mnps (multinomial 
propensity scores) function in the twang (Toolkit for Weighting and Analysis of 
Nonequivalent Groups) package in R Statistical Software (R Foundation for Statistical 
Computing, Vienna, Austria).7) Using the optimal truncation from Crump et al.,8) we used 
cases with a propensity score between 0.1 and 0.9 for weighted analyses. Logistic regression 
was used to assess the effect of each antiplatelet agent on 30-day clinical outcomes of death, 
MI, stroke, bleeding, and readmission. The baseline variables listed in Table 1 were used 
as covariates in multivariable logistic regression models. For weighted logistic regression 
analysis, we implemented the svyglm function in survey package, which enabled analyses to 
weight the data on combined propensity score and survey weights.
All statistical analyses were performed with R Statistical Software (version 3.3.2; R 
Foundation for Statistical Computing). P values <0.050 were considered indicative of 
statistically significant differences.
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Unweighted ASMD Weighted ASMD
Clopidogrel Prasugrel Ticagrelor Clopidogrel Prasugrel Ticagrelor
Age (years) 60 (52–68) 56 (49–62) 58 (51–65) 59 (51–67) <0.001 0.100 −0.301 −0.098 0.002 0.002 0.003
Female 4,843 (20) 398 (9) 1,762 (15) 7,003 (17) <0.001 0.162 −0.307 −0.096 0.005 −0.016 0.005
Hypertension 16,910 (69) 2,988 (69) 8,093 (68) 27,991 (69) 0.049 0.016 0.018 −0.026 0.001 0.006 −0.001
Diabetes mellitus 14,062 (57) 2,212 (51) 6,712 (56) 22,986 (56) <0.001 0.048 −0.112 −0.004 0.001 0.006 −0.014
Heart failure 4,865 (20) 687 (16) 2,298 (19) 7,850 (19) <0.001 0.037 −0.101 0.000 −0.003 −0.005 −0.001
Stroke 746 (3) 53 (1) 223 (2) 1,022 (3) <0.001 0.078 −0.130 −0.067 0.000 0.000 0.002
Hemodialysis 634 (3) 35 (1) 101 (1) 770 (2) <0.001 0.110 −0.134 −0.161 −0.007 −0.004 0.009
Clinical diagnosis <0.001
STEMI 7,588 (31) 1,979 (46) 4,853 (41) 14,420 (35) −0.241 0.238 0.152 0.000 0.002 0.001
NSTEMI 6,495 (27) 873 (20) 3,106 (26) 10,474 (26) 0.045 −0.151 0.011 0.000 −0.002 0.012
Unspecified MI 10,406 (42) 1,448 (34) 3,958 (33) 15,812 (39) 0.185 −0.122 −0.169 0.000 0.000 −0.012
Hospital capability (cases/years) <0.001
<50 4,575 (19) 259 (6) 1,682 (14) 6,516 (16) 0.172 −0.469 −0.077 0.004 −0.014 0.004
50–150 10,918 (45) 2,056 (48) 5,993 (50) 18,967 (47) −0.102 0.027 0.104 0.000 0.004 0.007
>150 8,996 (37) 1,985 (46) 4,242 (36) 15,223 (37) −0.034 0.197 −0.053 −0.003 0.006 −0.010
Hospitalization (days) <0.001
<7 9,806 (40) 1,850 (43) 5,086 (43) 16,742 (41) −0.056 0.043 0.044 0.000 0.004 −0.002
7–14 10,390 (42) 1,945 (45) 5,332 (45) 17,667 (43) −0.049 0.041 0.038 −0.002 −0.002 0.005
>14 4,293 (18) 505 (12) 1,499 (13) 6,297 (15) 0.136 −0.129 −0.123 0.003 −0.003 −0.005
Years at admission <0.001
2013 10,177 (42) 1,613 (38) 1,525 (13) 13,315 (33) 0.451 0.111 −0.843 0.001 0.004 −0.006
2014 7,779 (32) 1,441 (34) 4,605 (39) 13,825 (34) −0.118 −0.011 0.136 0.001 0.016 0.001
2015 6,533 (27) 1,246 (29) 5,787 (49) 13,566 (33) −0.377 −0.107 0.431 −0.002 −0.020 0.005
Data are presented as number (%) or median (IQR). ASMD was calculated as the difference in the mean rate of each variable between the treatment group and 
total population divided by the SD of the difference.
ASMD = absolute standardized mean difference; IQR = interquartile range; MI = myocardial infarction; NSTEMI = non-ST-segment elevation myocardial infarction; 
SD = standard deviation; STEMI = ST-segment elevation myocardial infarction.
RESULTS
Baseline clinical characteristics
Among a total of 40,706 AMI patients <75 years old who underwent PCI during admission 
between 2013 and 2015, the use of new antiplatelet agents, especially ticagrelor, has 
significantly increased since 2013 (Figure 1A). From 2010 to 2012, these agents were 
prescribed only for 1.2% patients with AMI during admission. The prescription rates of 
prasugrel and ticagrelor rapidly increased to 10.6% and 29.3% during 2013–2015, respectively 
(Figure 1B). Table 1 demonstrates the baseline clinical characteristics. The prasugrel and 
ticagrelor groups were younger and contained fewer females compared to the clopidogrel 
group. These new antiplatelet agents were more commonly prescribed for patients with 
STEMI. Prasugrel was less frequently used in patients with diabetes mellitus or heart failure. 
However, it was more commonly used in hospitals with more than 150 cases per year. 
Clopidogrel was preferred over new antiplatelet agents for AMI patients with a longer stay 
(>14 days) in the hospital.
Thirty-day clinical outcomes
Table 2 indicates the crude incidence of 30-day clinical adverse events. Mortality and admission 
rates within 30 days were lowest in AMI patients treated with prasugrel (1.4% and 5.7%, 
respectively) and highest in those treated with clopidogrel (3.4% and 6.9%, respectively). They 
were also significantly lower in the ticagrelor group compared to the clopidogrel group. There 
was no significant difference in reoccurrence of MI or bleeding rate based on antiplatelet agent 
use. However, stroke incidence was highest in patients with clopidogrel.
We conducted logistic regression models to analyze the impact of each new antiplatelet 
agent on clinical adverse events and applied a multivariable adjustment and/or propensity 
score weighting for each treatment (Table 3). Prasugrel was significantly correlated with 
lower incidence of 30-day mortality compared to clopidogrel. Using a crude model, the odds 
ratio (OR) for mortality was 0.41 (95% confidence interval [CI], 0.32–0.53; p<0.001). The 
OR was 0.46 (95% CI, 0.31–0.69; p<0.001) in the weighted multivariable model. Ticagrelor 
was correlated with a lower 30-day mortality rate compared to clopidogrel. The OR was 0.72 
(95% CI, 0.63–0.82; p<0.001) with the crude model and 0.84 (95% CI, 0.71–0.98; p=0.032) 
with a weighted multivariable model. The 30-day readmission rate was significantly lower in 
patients treated with new antiplatelet agents compared with those treated with clopidogrel. 
However, the adjusted models demonstrated that there was no significant impact of each 
new antiplatelet drug. Weighted multivariable models showed that the ORs of prasugrel 
and ticagrelor were 0.93 (95% CI, 0.78–1.12; p=0.456) and 1.01 (95% CI, 0.91–1.13; p=0.822), 
respectively. Regarding MI and bleeding, logistic regression models demonstrated no 
significant impact of new antiplatelet agents. We found that ticagrelor was significantly 
correlated with lower incidence of stroke (OR, 0.51; 95% CI, 0.33–0.80; p=0.003) in the 
crude model. Though there was a trend toward reduction in 30-day stroke risk with ticagrelor 
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Table 2. Incidence of 30-day clinical adverse events
30-day outcomes Clopidogrel (n=24,489) Prasugrel (n=4,300) Ticagrelor (n=11,917) p value
Mortality 842 (3.4) 62 (1.4) 298 (2.5) <0.001
MI 407 (1.7) 78 (1.8) 194 (1.6) 0.712
Stroke 96 (0.4) 10 (0.2) 24 (0.2) 0.006
Bleeding 30 (0.1) 5 (0.1) 14 (0.1) 0.988
Readmission 1,694 (6.9) 247 (5.7) 723 (6.1) 0.001
Data are presented as total number of events (%).
MI = myocardial infarction.
after multivariable adjustment (OR, 0.63; 95% CI, 0.39–1.01; p=0.054), weighted analyses 
displayed no significant impact of ticagrelor on stroke.
DISCUSSION
Using a nation-wide population from the HIRA Korean database, we demonstrated a 
contemporary pattern of P2Y12 antagonist use and its favorable impact on 30-day mortality 
in AMI patients undergoing PCI. The results of our study revealed major changes in the use 
of P2Y12 antagonists for patients with AMI in Korea between 2010 and 2015. New antiplatelet 
agent use grew rapidly, with a preference for ticagrelor over prasugrel. Until 2012, when new 
antiplatelet agents started to be covered by national health insurance, both prasugrel and 
ticagrelor were rarely prescribed for AMI patients. Between 2013 and 2015, approximately 
40% of AMI patients were treated with new antiplatelet agents. The prescription rate of new 
antiplatelet agents has been higher than that of clopidogrel since 2015.
Randomized trials demonstrated that both prasugrel1) and ticagrelor2) reduced major 
thromboembolic events, but had an elevated risk of bleeding compared to clopidogrel in 
patients with acute coronary syndrome. After 2012, American College of Cardiology/American 
Heart Association (ACC/AHA) guidelines for NSTEMI9) and STEMI10) were revised with a 
recommendation for the use of these drugs. However, the guidelines did not endorse prasugrel 
or ticagrelor over clopidogrel. There is a growing body of evidence to support new antiplatelet 
agents due to their rapid-onset, more potent platelet inhibition, and reduction in composite 
efficacy endpoints. In particular, the favorable impact on mortality of ticagrelor was proven 
by its landmark trial,2) unlike prasugrel.1) In addition, the strong preference of ticagrelor over 
prasugrel is attributable to prasugrell's contraindications (age >75 years, body weight <60 kg, 
and history of stroke) and lack of supporting evidence for clopidogrel's administration prior 
to diagnostic angiography (e.g., at the emergency room) and/or without revascularization.11) 
Contemporary practice guidelines3)5)12) recommend the use of new antiplatelet agents for 
patients with NSTEMI and STEMI. Despite similar recommendations for prasugrel and 
ticagrelor, the prescription rate of prasugrel has been gradually decreasing in Korea since 2013. 
A Swedish nationwide cohort study conducted between 2009 and 2013 also demonstrated a 
similar pattern of P2Y12 antagonist use among 104,012 patients with acute coronary syndrome. 
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Table 3. Adjusted ORs of ticagrelor and prasugrel for 30-day outcomes using logistic regression in the unweighted and IPTW models
30-day outcomes
Unweighted analysis Weighted analysis*
Univariable model Multivariable model† Univariable model Multivariable model†
OR 95% CI p value OR 95% CI p value OR 95% CI p value OR 95% CI p value
Prasugrel
Mortality 0.41 0.32–0.53 <0.001 0.58 0.45–0.76 <0.001 0.30 0.21–0.44 <0.001 0.46 0.31–0.69 <0.001
MI 1.09 0.86–1.40 0.475 1.27 0.99–1.64 0.058 0.94 0.69–1.28 0.711 1.09 0.79–1.50 0.617
Stroke 0.59 0.31–1.14 0.115 0.79 0.41–1.54 0.492 0.81 0.39–1.69 0.573 1.07 0.50–2.30 0.863
Bleeding 0.95 0.37–2.45 0.914 1.13 0.43–2.97 0.812 1.11 0.38–3.24 0.853 1.34 0.45–3.94 0.597
Readmission 0.82 0.71–0.94 0.005 0.97 0.84–1.12 0.699 0.79 0.66–0.93 0.006 0.93 0.78–1.12 0.456
Ticagrelor
Mortality 0.72 0.63–0.82 <0.001 0.86 0.75–0.99 0.040 0.84 0.73–0.98 0.028 0.84 0.71–0.98 0.032
MI 0.98 0.82–1.16 0.811 1.08 0.90–1.30 0.397 1.01 0.83–1.22 0.941 1.04 0.85–1.28 0.684
Stroke 0.51 0.33–0.80 0.003 0.63 0.39–1.01 0.054 0.73 0.43–1.24 0.247 0.77 0.44–1.36 0.370
Bleeding 0.96 0.51–1.81 0.897 1.05 0.54–2.05 0.892 0.76 0.39–1.51 0.438 0.72 0.37–1.41 0.335
Readmission 0.87 0.79–0.95 0.002 0.97 0.88–1.07 0.566 0.98 0.89–1.09 0.716 1.01 0.91–1.13 0.822
CI = confidential interval; IPTW = inverse probability of treatment weighting; MI = myocardial infarction; OR = odds ratio.
*Inverse probability of the treatment weighted estimation with propensity scores was computed using generalized boosted models as described in the Methods 
section, †Multivariable logistic regression model was used to adjust for the covariates shown in Table 1.
Ticagrelor became the predominant P2Y12 antagonist in patients undergoing angiography since 
2013, whereas clopidogrel was preferred in patients with noninvasive treatment in Sweden.13)
In this study, patients with longer hospital stay were less frequently prescribed prasugrel 
or ticagrelor. The reasons for lower utilization of new antiplatelet agents among such 
patients is unclear; however, these patients might have had more comorbidities or acute 
complications related to higher bleeding risk, which might make physicians hesitate to use 
clopidogrel instead of more potent drugs. The result of subgroup analyses from the Platelet 
Inhibition and Patient Outcomes (PLATO) trial demonstrated that the favorable effect of 
ticagrelor was consistent regardless of invasive treatment or Thrombolysis in Myocardial 
Infarction (TIMI) risk score at randomization.2)14)15) However, the Targeted Platelet Inhibition 
to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY 
ACS) trial concluded that prasugrel did not improve clinical outcomes in patients without 
revascularization.11) These results might support the use of ticagrelor among AMI patients 
regardless of successful revascularization, even in patients with higher bleeding risk at 
admission. However, further studies are required to determine the efficacy and safety of these 
drugs in patients with complications or deterioration during hospitalization.
In this study, 30-day mortality was significantly lower in patients receiving prasugrel (1.4%) 
or ticagrelor (2.5%) compared to those receiving clopidogrel (3.4%). The mortality rate of 
the clopidogrel group in the study was close to that of contemporary randomized trials and 
ranged from 2.4% to 3.2%.1)16-18) The mortality rates of the prasugrel and ticagrelor groups 
were also similar to the results of substudies of randomized trials, which showed 1.6% in 
Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in 
Myocardial Infarction 38 (TRITON-TIMI 38)19) and 2.6% in PLATO17) in STEMI patients. 
Prasugrel and ticagrelor were independently correlated with lower 30-day mortality after 
multivariable and weighted analysis in our study. As mentioned above, the favorable impact 
of ticagrelor on mortality was consistently demonstrated in various subgroup analyses of the 
PLATO trial, including in patients with invasive treatment,14) STEMI,17) diabetes,20) and renal 
dysfunction.21) Another registry in Sweden22) compared ticagrelor and clopidogrel and showed 
an association between ticagrelor and a lower risk of death, which was consistent with 
previous randomized trials and our study.
Even though TRITON-TIMI 381) demonstrated no beneficial impact of prasugrel on mortality 
in all participants, the substudy19) revealed a favorable effect of prasugrel on 30-day mortality 
in patients undergoing PCI for STEMI. Moreover, the favorable effect of prasugrel on mortality 
was also demonstrated by the TRITON-TIMI 38 sub-study with patients undergoing coronary 
artery bypass surgery.23) Furthermore, a meta-analysis including 10 randomized controlled trials 
and one large retrospective study drew the conclusion that prasugrel, but not ticagrelor, offered 
a significant reduction in 30-day mortality in PCI-treated STEMI patients.24) These results justify 
the utilization of prasugrel for patients who underwent revascularization.
There was no clinical impact of each new antiplatelet agent on 30-day MI mortality in the 
present study. Regarding composite efficacy endpoints including death, MI, and stroke, the 
superiority of prasugrel and ticagrelor has been demonstrated in previous studies. Better clinical 
efficacy of prasugrel was predominantly driven by a reduction in nonfatal MIs, rather than by 
reduction of death or stroke.1) Prasugrel had a consistent benefit on efficacy endpoints including 
MI, stent thrombosis, and revascularization during the first 3 days and for the duration of the 
study.25) It is remarkable that the incidence of MI within the first 3 days of that study was 4.3% 
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(prasugrel) and 5.2% (clopidogrel), which was significantly higher than our result, which ranged 
from 1.6% to 1.8%. We showed a similar incidence of bleeding in our study (0.1%), which is 
lower than seen in contemporary trials. Because of the limitations of our study, many events 
such as acute bleeding immediately following the procedure could have been excluded. Studies 
with a prospective design or a longer duration of follow-up might be warranted.
This study has some limitations. This study reflects the nation-wide and real-world practice 
of antiplatelet therapy for AMI patients and its clinical impact. However, there are some 
unavoidable limitations because of the study design.
First, we could not evaluate the severity of disease at the index hospitalization. Severity 
indices such as clinical presentation, left ventricular ejection fraction, cardiac biomarkers, 
blood pressure, and concomitant use of mechanical circulation support were not available. 
Furthermore, angiographic and procedural information, such as the extent of diseased 
vessels; type of intravascular procedure; and implanted number, length, or type of stent, were 
not accessible. We tried to adjust and balance such confounding factors affecting clinical 
outcomes. However, there might still be limitations even with the statistical analyses.
We conducted the analyses based on diagnostic code due to the limitations of this study 
design. There was a possibility that some mis-entry or omission of diagnostic codes occurred 
at the index hospitalization and during follow-up, which might lead to analytic inaccuracy. 
Regarding bleeding complications, we identified the events based on particular diagnostic 
codes without any additional information to determine clinical relevance; however, this 
did not allow for analysis of the severity of bleeding events. Because we could determine 
the adverse events during admission to healthcare centers after discharge from the index 
hospitalization, the adverse events that occurred during the index hospitalization or out of the 
hospital might have be missed. However, mortality data were independently recorded, and all 
readmission events were found in the database. The implications of antiplatelet agents on the 
outcomes, therefore, might be more credible than those of other clinical events.
Lack of information about other medications was one of the limitations of our study. This 
information can be relevant for optimal medical treatment. Instead, we tried to determine 
the adequacy of treatment for patients by adjusting for hospital capability for PCI cases and 
admission year. However, there are some limitations when comparing the implementation 
procedures and medications to assess the appropriateness of treatment.
In conclusion, we demonstrated the trend toward increasing use of new antiplatelet agents in 
AMI patients undergoing PCI in Korea. As a result, the new antiplatelet agents were shown 
to superior to clopidogrel for AMI in Korea since 2015. There was a favorable effect of both 
prasugrel and ticagrelor on 30-day mortality. However, each agent had no significant impact 
on the other 30-day clinical outcomes of MI, stroke, bleeding, and readmission in our study.
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